AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
IceCure Medical Ltd
Video analysis: ICCM
All videosNo video analysis for this stock yet. Request one from our team.
News: ICCM
IceCure Secures China NMPA Approval for ProSense Cryoablation System
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ -- IceCure Medical Ltd.
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
Agreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the highest complete ablation rate among evaluated thermal ablation technologies CAESAREA, Israel, Aug. 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into an exclusive distribution agreement (the "Agreement") with Scovas Medical ("Scovas") for the distribution of IceCure's ProSense® cryoablation systems in the Netherlands for breast cancer and interventional oncology.
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN CAESAREA, Israel, Aug. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approval for the Company's post-marketing study ("ChoICE Study") for ProSense® cryoablation in the local treatment of low-risk breast cancer.
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph node metastases CAESAREA, Israel, Aug. 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted two recent peer-reviewed publications by leading U.S. experts that reinforce the growing clinical role of cryoablation in breast cancer treatment de-escalation.
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash position CAESAREA, Israel, Aug. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial and operational results as of and for the six months ended June 30, 2026.
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval The site will be led by breast surgeon, Dr. Dennis Holmes, MD, FACS, a recognized leader in breast cancer cryoablation CAESAREA, Israel, August 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that Adventist Health Glendale in Glendale, California has signed an agreement and received approval from the Institutional Review Board to become the first clinical site able to enroll patients for the Company's post-marketing "ChoICE ," study (the "ChoICE Study"), for ProSense® in the local treatment of low-risk breast cancer following U.S Food and Drug Administration ("FDA") marketing authorization in October 2025.
